Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
BMC Public Health ; 13: 269, 2013 Mar 25.
Artigo em Inglês | MEDLINE | ID: mdl-23531102

RESUMO

BACKGROUND: The most appropriate public health approach to vaccine-associated measles in immunocompromised patients is unknown, mainly because these cases are rare and transmission of vaccine-associated measles has not been previously documented. In this case report, we describe Peel Public Health's response to a vaccine-associated measles case in an immunocompromised child in Ontario, Canada. CASE PRESENTATION: A five-year-old Canadian-born boy with a history of a hematopoetic stem cell transplant three years previously received live attenuated measles, mumps, and rubella (MMR) vaccine. Over the subsequent 7 to 14 days, he developed an illness clinically consistent with measles. There was no travel history or other measles exposure. Serology and polymerase chain reaction (PCR) testing confirmed acute measles infection. Following discussion with pediatric infectious diseases specialists, but prior to the availability of virus sequencing, it was felt that this case was most likely due to vaccine strain. Although no microbiologically confirmed secondary cases of vaccine-associated measles have been previously described, we sent notification letters to advise all contacts of measles symptoms since the likelihood of transmission from an immunocompromised patient was low, but theoretically possible. We decided to stratify contacts into immune competent and compromised and to deal with the latter group conservatively by excluding them as if they were exposed to wild-type measles because the risk of transmission of disease in this population, while presumably very low, is unknown. However, no contacts self-identified as immunocompromised and there were no secondary cases. Subsequent genotyping confirmed that this case was caused by vaccine strain measles virus. CONCLUSION: The public health approach to contact tracing and exclusions for vaccine-associated measles in immunocompromised patients is unclear. The rarity of secondary cases provides further evidence that the risk to the general public is likely extremely low. Although the risk appears negligible, exclusion and administration of immune globulin may be considered for susceptible, immunocompromised contacts of cases of vaccine-associated measles in immunocompromised patients.


Assuntos
Hospedeiro Imunocomprometido , Vacina contra Sarampo-Caxumba-Rubéola/efeitos adversos , Sarampo/etiologia , Prática de Saúde Pública , Pré-Escolar , Busca de Comunicante , Transplante de Células-Tronco Hematopoéticas , Humanos , Masculino , Ontário , Vacinas Atenuadas/efeitos adversos
2.
BMC Public Health ; 11: 234, 2011 Apr 14.
Artigo em Inglês | MEDLINE | ID: mdl-21492445

RESUMO

BACKGROUND: Understanding transmission dynamics of the pandemic influenza A (H1N1) virus in various exposure settings and determining whether transmissibility differed from seasonal influenza viruses was a priority for decision making on mitigation strategies at the beginning of the pandemic. The objective of this study was to estimate household secondary attack rates for pandemic influenza in a susceptible population where control measures had yet to be implemented. METHODS: All Ontario local health units were invited to participate; seven health units volunteered. For all laboratory-confirmed cases reported between April 24 and June 18, 2009, participating health units performed contact tracing to detect secondary cases among household contacts. In total, 87 cases and 266 household contacts were included in this study. Secondary cases were defined as any household member with new onset of acute respiratory illness (fever or two or more respiratory symptoms) or influenza-like illness (fever plus one additional respiratory symptom). Attack rates were estimated using both case definitions. RESULTS: Secondary attack rates were estimated at 10.3% (95% CI 6.8-14.7) for secondary cases with influenza-like illness and 20.2% (95% CI 15.4-25.6) for secondary cases with acute respiratory illness. For both case definitions, attack rates were significantly higher in children under 16 years than adults (25.4% and 42.4% compared to 7.6% and 17.2%). The median time between symptom onset in the primary case and the secondary case was estimated at 3.0 days. CONCLUSIONS: Secondary attack rates for pandemic influenza A (H1N1) were comparable to seasonal influenza estimates suggesting similarities in transmission. High secondary attack rates in children provide additional support for increased susceptibility to infection.


Assuntos
Características da Família , Vírus da Influenza A Subtipo H1N1 , Influenza Humana/epidemiologia , Pandemias , Vigilância da População , Adolescente , Adulto , Idoso , Criança , Pré-Escolar , Busca de Comunicante , Feminino , Humanos , Lactente , Influenza Humana/transmissão , Masculino , Pessoa de Meia-Idade , Ontário/epidemiologia , Estudos Prospectivos , Fatores de Risco , Estações do Ano , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA